Jan 31, 2024 / 11:30AM GMT
Operator
Ladies and gentlmen, good day and welcome to Ajanta Pharma Q3 FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you and over to you, sir.
Yogesh Agrawal - Ajanta Pharma Ltd - Managing Director, Executive Director
Thank you. Good evening, everyone, and welcome to this earnings call. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, our CFO; and Mr. Rajeev Agrawal, our EVP, Finance and Investor Relations.
I hope that the results are already there with you. We will take you through the business-wise performance for the Q3 and nine months of the current year, along with the comparison of previous year same period.
I am pleased to inform you that the Board of Directors have approved the second interim dividend for the current year. The share of INR2 face value will receive a dividend of INR26 amounting to the dividend amount of INR327 crore. In
Q3 2024 Ajanta Pharma Ltd Earnings Call Transcript
Jan 31, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers